RLF — RELIEF THERAPEUTICS Holding SA Income Statement
0.000.00%
Last trade - 00:00
- CH₣16.01m
- CH₣7.77m
- CH₣6.08m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.565 | 0 | 0 | 3.32 | 6.08 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 2.57 | 4.83 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1.06 | 12.1 | 5.7 | 37.6 | 58.1 |
Operating Profit | -0.5 | -12.1 | -5.7 | -34.3 | -52 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.416 | -12.2 | -6.26 | -35.5 | -54.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.436 | -7.46 | -7.83 | -34.7 | -50.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.436 | -7.46 | -7.83 | -34.7 | -50.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.436 | -7.46 | -7.83 | -34.7 | -50.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.085 | -0.034 | -2.87 | -3.81 | -3.18 |
Dividends per Share |